Physician profile
Holly Willis
NPI 1275989345
$3,553.69
in general payments reported to CMS, 2019-2025
31 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $502 · 2022: $405 · 2023: $545 · 2024: $929 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,506 · Education: $141.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,505.92 |
| Education | $140.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $822.52 | 2021-2025 | Opdivo, Opdualag |
| Amgen INC. | $547.31 | 2022-2024 | |
| Janssen Biotech, INC. | $306.52 | 2024-2025 | Tecvayli, Carvykti, Darzalex |
| Novartis Pharmaceuticals Corporation | $182.51 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $144.29 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Janssen Pharmaceuticals, INC | $138.14 | 2023 | Xarelto |
| Abbvie INC. | $123.73 | 2023-2025 | |
| Tg Therapeutics, INC. | $120.81 | 2021 | |
| Gilead Sciences, INC. | $116.08 | 2025 | Trodelvy |
| Pharmaessentia USA Corporation | $113.97 | 2023 | Besremi |
| Jazz Pharmaceuticals INC. | $90.56 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $87.89 | 2024-2025 | Fruzaqla, Ninlaro |
| Genmab U.S., INC. | $73.72 | 2024-2025 | Epkinly, Tivdak |
| Cumberland Pharmaceuticals, INC. | $68.73 | 2025 | Sancuso |
| Astellas Pharma US INC | $67.04 | 2025 | Xtandi, Padcev |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $62.30 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $58.53 | 2024-2025 | Ultomiris |
| Eisai INC. | $52.79 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $50.29 | 2024-2025 | Libtayo |
| Sanofi-Aventis U.S. LLC | $41.99 | 2024 | |
| Array Biopharma INC | $35.50 | 2024-2025 | Braftovi, Lorbrena, Xalkori |
| Genentech USA, INC. | $30.50 | 2025 | Venclexta |
| Blueprint Medicines Corporation | $30.13 | 2024 | Ayvakit |
| Puma Biotechnology, INC. | $29.13 | 2025 | |
| Genzyme Corporation | $26.78 | 2025 | |
| Syndax Pharmaceuticals, INC. | $23.60 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $23.21 | 2025 | Tagrisso |
| Celgene Corporation | $22.69 | 2025 | Reblozyl |
| Aveo Pharmaceuticals, INC. | $21.91 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.29 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.23 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Holly Willis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.